Therapeutic Response

PR positive status confers therapeutic sensitivity to Exemestane in patients with Invasive Breast Carcinoma.

Statements

Source and description
Exemestane Monotherapy. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved exemestane for reimbursement as a monotherapy treatment option for the adjuvant treatment of hormone receptor positive invasive early breast cancer in patients who are postmenopausal women.